Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
(Nasdaq: MIRM) today announced that the European Commission has granted marketing authorization for LIVMARLI® (maralixibat) oral solution for the …Read More
The Heartbeat of World events
(Nasdaq: MIRM) today announced that the European Commission has granted marketing authorization for LIVMARLI® (maralixibat) oral solution for the …Read More